Hard to Treat Diseases (HTDS.PK) Mellow Hope, an operating subsidiary of HTDS, is pleased to report that its clinical trial is currently being processed. The company expects it will be completed by this September (Approx 60 days). The company expects the manufacturing license will be released by October or November of this year.
H1N1 (referred to as "swine flu" early on) is a new influenza virus causing illness in people. This new virus was first detected in people in the United States in April 2009. This virus is spreading from person-to-person worldwide, probably in much the same way that regular seasonal influenza viruses spread. On June 11, 2009, the World Health Organization (WHO) signaled that a pandemic of novel H1N1 flu was underway.
Terry Yuan CEO of HTDS said (sic) "With the new H1N1 virus continuing to cause illness, hospitalizations and deaths in the whole world, it is highly recommended to make preparation for a voluntary H1N1 vaccination. Mellow Hope is the only one H1N1 vaccine supplier for the overseas market from China."
The company intends to provide many further timely updates from both of its China , and Serbia based operations.
Review highlights failures in global control strategies for bird flu transmission